Subclinical carotid atherosclerosis in patients with psoriatic arthritis

Arthritis Care and Research

Volumn 59, Issue 9, 2008, Pages 1322-1331

  Tam, Lai Shan ^a   Shang, Qing ^a   Li, Edmund K ^a   Tomlinson, Brian ^a   Chu, Tanya T W ^a   Li, Martin ^a   Leung, Ying Ying ^b   Kwok, Lai Wa ^a   Wong, Kong Chiu ^a   Li, Tena K ^a   Yu, Tracey ^a   Zhu, Tracy Y ^a   Kun, Emily W ^b   Yip, Gabriel W ^a   Yu, Cheuk Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Taipo Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PSORIATIC ARTHRITIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 54949134070     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24014     Document Type: Article

References (35)

1. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
2. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
3. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
4. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls: the role of inflammation. Rheumatology (Oxford) 2008;47:718-23.
5. Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992;22:172-8.
6. Skoczynska AH, Turczyn B, Barancewicz-Losek M, Martynowicz H. High-density lipoprotein cholesterol in patients with psoriatic arthritis [letter]. J Eur Acad Dermatol Venereol 2003;17:362-3.
7. Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis 2000;59:904-9.
8. Persson J, Formgren J, Israelsson B, Berglund G. Ultrasound-determined intima-media thickness and atherosclerosis: direct and indirect validation. Arterioscler Thromb 1994;14:261-4.
9. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
10. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80.
11. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
13. Van der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
14. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
15. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-8.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
17. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
18. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies [published erratum appears in Lancet 2004;363:902]. Lancet 2004;363:157-63.
21. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005;366:1059-62.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
24. Inoue S, Zimmet P, Caterson I, Chunming C, Ikeda Y, Khalid AK, et al. The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health Communications Australia Pty Limited; 2000. p. 1-56.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
26. Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007;93:933-9.
27. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G. Noninvasive quantification of atherosclerotic lesions: reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992;12:261-6.
28. Roman MJ, Saba PS, Pini R, Spitzer M, Pickering TG, Rosen S, et al. Parallel cardiac and vascular adaptation in hypertension. Circulation 1992;86:1909-18.
29. Joakimsen O, Bonaa KH, Stensland-Bugge E. Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology: the Tromsø Study. Stroke 1997;28:2201-7.
30. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol 1997;146:483-94.
31. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 2007;115:459-67.
32. Grewal J, Anand S, Islam S, Lonn E, for the SHARE and SHARE-AP Investigators. Prevalence and predictors of subclinical atherosclerosis among asymptomatic "low risk" individuals in a multiethnic population. Atherosclerosis 2008;197:435-42.
33. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al, for the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
34. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
35. Liu J, Hong Y, D'Agostino RB Sr, Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004;291:2591-9.